EUCTR2020-000112-29-NL
Active, not recruiting
Phase 1
[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer
eiden University Medical Center0 sites15 target enrollmentFebruary 27, 2021
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- eiden University Medical Center
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with radiologically FIGO stage IIIB/IIIC EOC based on the conventional CT scan who are
- •scheduled to undergo primary cytoreductive surgery and
- •a)in whom EOC is histologically proven, or
- •b)in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 \[2,22] is found
- •treated with neoadjuvant chemotherapy (NACT) and are scheduled to undergo interval cytoreductive surgery and
- •a)in whom EOC is histologically proven, or
- •b)in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 \[2,22] was found before NACT
- •c)and with radiologically FIGO stage IIIB/IIIC EOC based on the response evaluation CT scan after NACT
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •1\. Women younger than 30 years of age (in accordance with the guidelines of the Netherlands Commission on Radiation Dosimetry, as the total radiation dose will be 7\.2 mSv)
- •2\. Patients who previously underwent primary laparotomy and in whom complete or optimal cytoreduction was not considered feasible.
- •3\. Contraindication for PET (pregnancy, lactating or severe claustrophobia)
- •4\. Impaired renal function (defined as eGFR \< 50 mL/1\.73 m2\)
- •5\. Impaired liver function (ALT, AST or total bilirubin \> 3x upper limit of normal)
- •6\. Clinically significant abnormalities on ECG and/or clinically laboratory test
- •7\. Inability to tolerate lying supine for the duration of a PET/CT examination (\~110 minutes)
- •8\. Patients with concomitant malignancy (except basal cell carcinoma of the skin) or any condition that in the opinion of the investigators could potentially jeopardize the health status of the patient
- •9\. Patients not able to comply with the study procedures
- •10\. Patients who did not give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancerEpithelial ovarian cancer10033283NL-OMON52813eids Universitair Medisch Centrum15
Active, not recruiting
Phase 1
Monitoring of respons to therapy in rheumatoid arthritis with the help of a PET scan.Rheumatoid ArthritisTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2018-004429-94-NLVU Medical Center, department of Rheumatology10
Not yet recruiting
Phase 2
[18F]fluor-PEG-folate PET/CT imaging in Giant Cell Arteritis.NL-OMON52861niversitair Medisch Centrum Groningen10
Recruiting
Phase 2
Macrophage imaging GCA2024-514491-40-00Universitair Medisch Centrum Groningen10
Recruiting
Not Applicable
[18F]Fluoride PET-CT imaging for detection and monitoring of bone formation in spondyloarthritisNL-OMON52517Vrije Universiteit Medisch Centrum48